Literature DB >> 18333161

Non-surgical treatment of hepatocellular carcinoma.

Philip J Johnson1.   

Abstract

A wide variety of non-surgical therapies can result in clinical responses in patients with hepatocellular carcinoma. Two recent studies have suggested that transarterial chemoembolisation can, in highly selected patients with good liver function, result in an improvement in survival. No other approaches have, to date, demonstrated convincing evidence of survival advantage.

Entities:  

Year:  2005        PMID： 18333161      PMCID： PMC2023922          DOI： 10.1080/13651820410024076

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


  49 in total

1.  Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection.

Authors:  K N Khan; H Yatsuhashi; K Yamasaki; M Yamasaki; O Inoue; M Koga; M Yano
Journal:  J Hepatol       Date:  2000-02       Impact factor: 25.083

2.  Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial.

Authors:  C Grimaldi; H Bleiberg; F Gay; M Messner; P Rougier; T C Kok; L Cirera; A Cervantes; J De Greve; B Paillot; M Buset; D Nitti; T Sahmoud; N Duez; J Wils
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

Review 3.  Clinical trials in primary hepatocellular carcinoma: current status and future directions.

Authors:  S R Nerenstone; D C Ihde; M A Friedman
Journal:  Cancer Treat Rev       Date:  1988-03       Impact factor: 12.111

4.  Postoperative recurrence of hepatocellular carcinoma.

Authors:  T Nagao; S Inoue; F Yoshimi; M Sodeyama; Y Omori; T Mizuta; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

Review 5.  Clinical pharmacology of hepatic arterial chemotherapy.

Authors:  W D Ensminger; J W Gyves
Journal:  Semin Oncol       Date:  1983-06       Impact factor: 4.929

6.  Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.

Authors:  J Belghiti; Y Panis; O Farges; J P Benhamou; F Fekete
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

7.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

8.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Authors:  G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

9.  Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery.

Authors:  I Okayasu; S Hatakeyama; T Yoshida; S Yoshimatsu; K Tsuruta; H Miyamoto; Y Kimula
Journal:  Am J Clin Pathol       Date:  1988-11       Impact factor: 2.493

10.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.

Authors:  T Livraghi; A Giorgio; G Marin; A Salmi; I de Sio; L Bolondi; M Pompili; F Brunello; S Lazzaroni; G Torzilli
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105
View more
  16 in total

1.  Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.

Authors:  Na Shang; Hao Wang; Thomas Bank; Aldeb Perera; Cara Joyce; Gina Kuffel; Michael J Zilliox; Scott J Cotler; Xianzhong Ding; Asha Dhanarajan; Peter Breslin; Wei Qiu
Journal:  Hepatology       Date:  2019-06-22       Impact factor: 17.425

Review 2.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.

Authors:  Na Shang; Maribel Arteaga; Ali Zaidi; Scott J Cotler; Peter Breslin; Xianzhong Ding; Paul Kuo; Michael Nishimura; Jiwang Zhang; Wei Qiu
Journal:  Gene Expr       Date:  2016-05-02

4.  FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

Authors:  Na Shang; Maribel Arteaga; Ali Zaidi; Jimmy Stauffer; Scott J Cotler; Nancy J Zeleznik-Le; Jiwang Zhang; Wei Qiu
Journal:  Hepatology       Date:  2014-11-25       Impact factor: 17.425

5.  Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Authors:  Sadakatsu Ikeda; Jordan S Lim; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

Review 6.  HBV induced HCC: major risk factors from genetic to molecular level.

Authors:  Ambreen Ayub; Usman Ali Ashfaq; Asma Haque
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

7.  Alantolactone induces apoptosis in HepG2 cells through GSH depletion, inhibition of STAT3 activation, and mitochondrial dysfunction.

Authors:  Muhammad Khan; Ting Li; Muhammad Khalil Ahmad Khan; Azhar Rasul; Faisal Nawaz; Meiyan Sun; Yongchen Zheng; Tonghui Ma
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

8.  Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.

Authors:  Baolai Zhang; Shuhong Dong; Zhongxin Li; Li Lu; Su Zhang; Xue Chen; Xiaobo Cen; Yongjie Wu
Journal:  J Transl Med       Date:  2015-11-05       Impact factor: 5.531

9.  New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma.

Authors:  Hor-Yue Tan; Ning Wang; Masao Takahashi; Yigang Feng; Hongyun Li; Yibin Feng
Journal:  Int J Mol Sci       Date:  2016-08-05       Impact factor: 5.923

10.  Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.

Authors:  Jon Voutila; Vikash Reebye; Thomas C Roberts; Pantelitsa Protopapa; Pinelopi Andrikakou; David C Blakey; Robert Habib; Hans Huber; Pal Saetrom; John J Rossi; Nagy A Habib
Journal:  Mol Ther       Date:  2017-08-04       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.